Search

US-12616726-B2 - Probiotic supplement for metabolic health

US12616726B2US 12616726 B2US12616726 B2US 12616726B2US-12616726-B2

Abstract

The application discloses Lactobacillus strains having a beneficial effect on the metabolic health on a mammalian subject. Further disclosed is compositions comprising such strains and the use thereof for improving the metabolic health or for lowering the blood glucose level in a mammalian subject.

Inventors

  • Nanna Ny Kristensen
  • DELPHINE MARIE ANNE SAULNIER
  • JEFFREY SCHULTCHEN
  • ALEXANDRA MATTERN
  • TEIS JENSEN
  • BENJAMIN ANDERSCHOU HOLBECH JENSEN

Assignees

  • NOVOZYMES A/S

Dates

Publication Date
20260505
Application Date
20240327
Priority Date
20181024

Claims (13)

  1. 1 . A method of alleviating prediabetes or lowering the blood glucose level of an individual in need thereof, the method comprising administering to the individual Lactobacillus strain DSM 32851.
  2. 2 . The method of claim 1 , wherein the method results in improving or alleviating one or more prediabetes symptoms in the individual selected from insulin resistance, high-blood glucose, low-grade inflammation and gut barrier function.
  3. 3 . The method of claim 1 , wherein the individual is a human.
  4. 4 . The method of claim 1 , wherein the individual is a mammalian subject.
  5. 5 . The method of claim 1 , wherein the strain is in freeze-dried form.
  6. 6 . The method of claim 1 , wherein the strain is in spray-dried form.
  7. 7 . The method of claim 1 , wherein the stain is administered as composition comprising 10 6 -10 14 colony forming units (CFU) of total Lactobacillus strain per gram of the composition.
  8. 8 . The method of claim 1 , wherein the stain is administered as composition comprising 10 7 -10 13 colony forming units (CFU) of total Lactobacillus strain per gram of the composition.
  9. 9 . The method of claim 1 , wherein the stain is administered as composition comprising 10 8 -10 12 colony forming units (CFU) of total Lactobacillus strain per gram of the composition.
  10. 10 . The method of claim 1 , wherein the strain survives in the gastrointestinal (GI) tract.
  11. 11 . The method of claim 1 , comprising administering strain Lactobacillus DSM 32851 together with one or more Lactobacillus strains DSM 17648, DSM 32910, DSM 32911 and DSM 32853.
  12. 12 . The method of claim 1 , comprising administering strain Lactobacillus DSM 32851 together with Lactobacillus DSM 32910.
  13. 13 . The method of claim 1 , wherein the strain is administered orally.

Description

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. patent application Ser. No. 17/287,719 which is a 35 U.S.C. 371 national application of PCT/EP2019/079027, filed Oct. 24, 2019, which claims priority or the benefit from European Patent Application 18202187.3, filed Oct. 24. 2018. The contents of these applications are fully incorporated herein by reference. REFERENCE TO A DEPOSIT OF BIOLOGICAL MATERIAL This application contains a reference to a deposit of biological material, which deposit is incorporated herein by reference. For complete information see last paragraph of the description. FIELD OF THE INVENTION The present invention relates to bacterial strains, cell components, metabolites and secreted molecules thereof having the ability of improving the metabolic health of a mammalian subject. The application also relates to composition comprising such bacterial strains and the use of such compositions to improve the metabolic health of a mammalian subject. BACKGROUND OF THE INVENTION In recent years, it has been shown several times that bacteria have an important and significant impact on the health of mammalians, in particular human beings, and it has been realized that a beneficial microbiota in the gastrointestinal tract is important for the proper nutrition and wellbeing. Intake of microbial cultures or strains, also termed probiotics, has now been recognized as a way to improve the health of individuals using the microbial cultures or strains. In this connection and throughout the description and claims the terms probiotics, microbial cultures and microbial strains are understood in the generally accepted way as “live microorganisms, which when administered in adequate amounts, confer a health benefit to the host” (http://www.nature.com/articles/nrgastro.2014.66?foxtrotcallback=true). Microbial strains can be used both for improving an unsatisfactory health status in an individual and for preventing that the unsatisfactory health situation arises. The beneficial property of probiotics depends on the property of the microbial strain that form the probiotics and it is therefore important to provide new microbial strains having beneficial properties that allows the strains to be used as probiotics. SUMMARY OF THE INVENTION In a first aspect, the invention relates to a Lactobacillus strain having the ability of improving the metabolic health, such as alleviating prediabetes, of a mammalian subject. In a further or alternative aspect, the Lactobacillus strain of the invention has the ability to lower the blood glucose level in a mammalian subject. The Lactobacillus strain of the invention may e.g. be a strain deposited at DSMZ—“German Collection of Microorganisms and Cell Cultures” under the deposit numbers: DSM 17648, DSM 32851, DSM 32853, DSM 32910 and/or DSM 32911. In a second aspect, the invention relates to a composition comprising one or more Lactobacillus strains of the invention, preferably formulated in discrete dosage formulations. In a third aspect, the invention relates to the use one or more Lactobacillus strains of the invention or a composition comprising one or more Lactobacillus strains of the invention for the improvement of the metabolic health, such as alleviating prediabetes, in mammalian subject, for maintaining of normal blood glucose level and/or reducing postprandial glycemic response in an individual, preventing or alleviating insulin resistance, or for preventing or reducing weight gain in an individual having a high fat and/or high sugar diet. Finally, in a fourth aspect the invention relates to a method for screening for a Lactobacillus strain having the ability of improving the metabolic health, such as alleviating prediabetes, of a mammalian subject. BRIEF DESCRIPTION OF DRAWINGS FIG. 1 shows a bar graph representing the ratio of anti-inflammatory cytokine interleukin 10 (IL10) and pro-inflammatory cytokine interleukin 12 (IL12) measured by Luminex or ELISA in the supernatants of peripheral blood mononuclear cells (PBMCs) incubated with Lactobacillus strains for 24 h. Each column represents the mean of 3 experiments performed with healthy PBMC donors. For more details see example 2. FIG. 2 shows a bar graph representing the pro-inflammatory cytokine monocyte chemoattractant protein 1 (MCP-1) measured by Luminex in the supernatants of PBMCs stimulated with a pro-inflammatory stimulus (lipopolysaccharide) and incubated with Lactobacillus strains for 24 h. Each column represents the mean of 3 experiments performed with healthy PBMC donors. For more details see example 2. FIG. 3 shows a bar graph representing the pro-inflammatory osteopontin measured by Luminex in the supernatants of PBMCs stimulated with a pro-inflammatory stimulus (lipopolysaccharide) and incubated with Lactobacillus strains for 24 h. Each column represents the mean of 3 experiments performed with healthy PBMC donors. For more details see example 2. FIG. 4 shows bar graphs sh